Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting. (PROTECT)
Congestive Heart Failure
About this trial
This is an interventional treatment trial for Congestive Heart Failure focused on measuring congestive heart failure treatment, congestive heart failure, prognosis, NT-proBNP testing
Eligibility Criteria
Inclusion Criteria: Age > 21 years of age Left ventricular ejection fraction ≤ 40% NYHA class II-IV heart failure Hospital admission, Emergency Department visit, or outpatient diuretic escalation of therapy for destabilized HF at least once in the 6 months prior to enrollment Exclusion Criteria: Severe renal insufficiency defined as serum creatinine > 2.5 mg/dl Inoperable aortic valvular heart disease Life expectancy <1 year due to causes other than HF such as advanced cancer Cardiac transplantation or revascularization indicated or expected within 6 months Severe obstructive or restrictive pulmonary disease, defined as a forced expiratory volume in 1S <1 L when diagnosed as standard of care. Subject unable or unwilling to provide written informed consent Coronary revascularization (PCI or CABG) within the previous 3 months
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
SOC
NT-proBNP arm
Standard of care HF therapy without NT-proBNP guidance
NT-proBNP plus standard HF management